ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+12.77%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$616M
AUM Growth
+$616M
(+19%)
Cap. Flow
+$33.1M
Cap. Flow
% of AUM
5.37%
Top 10 Holdings %
Top 10 Hldgs %
49.49%
Holding
239
New
40
Increased
61
Reduced
56
Closed
33
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$52.1M |
| 2 |
Prothena Corp
PRTA
|
$20.5M |
| 3 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 4 |
CytomX Therapeutics
CTMX
|
$6.89M |
| 5 |
ABVX
Abivax
ABVX
|
$6.59M |
Top Sells
| 1 |
RAPT Therapeutics
RAPT
|
$41.5M |
| 2 |
Roivant Sciences
ROIV
|
$17.4M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$8.63M |
| 4 |
Immunovant
IMVT
|
$6.94M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.34M |
Sector Composition
| 1 | Healthcare | 83.61% |
| 2 | Financials | 2.95% |
| 3 | Consumer Discretionary | 0% |
| 4 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BSAAU
76
BEST SPAC I Acquisition Corp. Unit
BSAAU
$58.3M
| $1M | 0.15% |
+100,000
| New | +$1M |
|
77
argenx
ARGX
$43.6B
| $970K | 0.15% |
1,759
+1,159
| +193% | +$639K |
|
78
Merus
MRUS
$4.98B
| $963K | 0.15% |
18,313
-48,647
| -73% | -$2.56M |
|
79
Aldeyra Therapeutics
ALDX
$351M
| $957K | 0.15% |
249,920
+38,341
| +18% | +$147K |
|
80
Pfizer
PFE
$141B
| $955K | 0.15% |
39,400
-1,650
| -4% | -$40K |
|
81
Arvinas
ARVN
$568M
| $948K | 0.15% |
128,767
-184,587
| -59% | -$1.36M |
|
82
Arcellx
ACLX
$3.85B
| $919K | 0.14% |
13,962
| – | – |
|
83
Nuvalent
NUVL
$5.52B
| $904K | 0.14% |
+11,842
| New | +$904K |
|
84
Tenax Therapeutics
TENX
$27.3M
| $896K | 0.14% |
155,557
+86,816
| +126% | +$500K |
|
85
Surgery Partners
SGRY
$2.91B
| $889K | 0.14% |
40,000
| – | – |
|
86
Arrowhead Research
ARWR
$3.05B
| $872K | 0.13% |
55,200
-1,100
| -2% | -$17.4K |
|
87
Korro Bio
KRRO
$217M
| $859K | 0.13% |
68,815
+100
| +0.1% | +$1.25K |
|
88
Keen Vision Acquisition Corp
KVAC
| $853K | 0.13% |
+75,000
| New | +$853K |
|
89
VistaGen Therapeutics
VTGN
$102M
| $842K | 0.13% |
420,765
| – | – |
|
90
Apogee Therapeutics
APGE
$2.17B
| $785K | 0.12% |
18,070
-86,783
| -83% | -$3.77M |
|
91
Wave Life Sciences
WVE
$1.53B
| $746K | 0.11% |
114,814
+91,714
| +397% | +$596K |
|
92
KALA BIO
KALA
$78.8M
| $713K | 0.11% |
149,830
-149,125
| -50% | -$710K |
|
93
Larimar Therapeutics
LRMR
$310M
| $687K | 0.11% |
+237,605
| New | +$687K |
|
94
Rocket Pharmaceuticals
RCKT
$354M
| $676K | 0.1% |
275,800
+34,000
| +14% | +$83.3K |
|
95
Kezar Life Sciences
KZR
$28.9M
| $675K | 0.1% |
147,404
| – | – |
|
96
Xencor
XNCR
$580M
| $675K | 0.1% |
85,826
-312,326
| -78% | -$2.45M |
|
|
CTNM
97
Contineum Therapeutics
CTNM
$293M
| $662K | 0.1% |
166,799
-1,966
| -1% | -$7.81K |
|
98
Biogen
BIIB
$19.4B
| $641K | 0.1% |
5,100
+600
| +13% | +$75.4K |
|
99
Geron
GERN
$893M
| $622K | 0.1% |
441,176
+175,000
| +66% | +$247K |
|
100
Phathom Pharmaceuticals
PHAT
$864M
| $608K | 0.09% |
63,424
+20,624
| +48% | +$198K |
|